The global ENT devices market is anticipated to contribute $15.5 billion by 2022 growing at a CAGR of 7% during 2016-2022. The ENT devices market is segmented on the basis of product type which includes diagnostic devices, surgical devices, image-guided surgery systems, hearing implants, Co2 lasers and hearing aids. Currently, hearing aid segment holds the largest market share in ENT devices market. In 2015, more than 11 million people have some form of hearing loss in UK. It is anticipated that there will be 15.6 million people with hearing loss in the UK by 2035. Approx. 6.7 million people could benefit from hearing aids in the UK. Increasing prevalence of hearing loss problems is expected to significantly influence the demand for hearing aids in the coming years. CO2 lasers are also anticipated to witness significant growth in the upcoming period. Carbon dioxide lasers are increasingly becoming a first line treatment of early stage airway cancers.
For more information about this report: http://www.reportsweb.com/global-ent-market-insights-opportunity-analysis-market-shares-and-forecast-2016-2022
Various studies have observed that adaptation of CO2 lasers leads to considerable cost savings and better or equivalent treatment outcomes for transoral laser resection of laryngeal tumors in comparison with radiation. The use of cold knife surgery, radiation therapy or chemotherapy in the treatment of transoral airway cancer is linked with complications that can dramatically alter facial appearance and impact the ability to talk, swallow, smell, hear, eat, taste and breathe normally. On the other hand, TLM (transoral laser microsurgery) done with CO2 laser, offers excellent cure rates compared to chemo or radiation as well as also results in low morbidity. The ENT devices market is dominated by some major companies such as Medtronic PLC, Stryker Corporation, Sonova Holdings AG, Acclarent Inc., William Demant Holdings A/S and Cochlear Limited.
The ENT devices market is majorly driven by rapidly growing geriatric population and high prevalence rate of chronic sinusitis. Asia Pacific had highest geriatric population (above 60 years) of 508 million in 2015. Presence of high geriatric population leads to more cases of ENT problems.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001329494/sample
Chronic sinusitis can be caused by multiple factors including allergies, structural defects of the nose that interfere with breathing, infectious diseases such as measles and pneumonia, upper respiratory infections that spread through the sinuses, air pollution, sudden extremes of temperature. In 2015, the prevalence rate of chronic rhinosinusitis in Canada is anticipated to be 5%. Moreover, this prevalence rate is expected to be increased in the upcoming years due to increasing pollution level and changing lifestyle. High cost of ENT devices and procedures is a key restraint in the growth of ENT devices market. Lack of skilled otolaryngologists is the major challenges before ENT devices market.
The report segmented ENT devices market on the basis of product type, end-users and regions. The country level analysis of each geographical region is the USP of our report. The analysis of the report is based on various parameters such as adoption rate of ENT devices in various regions, demand across various end-users and prevalence rate of sinusitis across globe and price of devices across regions. The data is collected through primary and secondary research. The report provides detailed analysis of key market players and their strategies.
1. ATOS MEDICAL AB.
2. KARL STORZGMBH& CO. KG
3. STRYKER CORPORATION
4. OLYMPUS CORPORATION
5. COCHLEAR LIMITED
6. SONOVA HOLDING AG
7. MEDTRONIC PLC
8. SMITH & NEPHEW PLC
9. ACCLARENT, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON)
10. HOYA CORPORATION
11. WILLIAM DEMANT HOLDING A/S
12. WIDEX A/S
13. SIEMENS HEALTHCARE
14. STARKEY LABORATORIES INC.
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001329494/buying